latest news releases from the newsroom
Active Biotech to Present at the SG Cowen & Company 6th Annual
STOCKHOLM, Sweden, Nov. 3, 2005 (PRIMEZONE) -- Active Biotech (Stockholm: ACTI.ST) management will present at the SG Cowen & Company 6th Annual Global Health Care Conference at 16.20 (CET) / 10:40 a.m. (ET) on Thursday, November 10 at The Hilton Diagonal Mar, in Barcelona, Spain. During the presentation, management will provide an update on the Active Biotech development program, as well as offer insight into its financial results.The presentation will include an update on the following drugs: laquinimod, the company's oral MS drug for which it is in partnership with Teva Pharmaceutical Industries Ltd.; ANYARA, Active Biotech's novel concept for the treatment of lung cancer; and other key projects in clinical development, such as TASQ, for prostate cancer; 57-57, for Lupus (SLE); and RhuDex(R) (licensed to Avidex Ltd.) for rheumatoid arthritis.
Metso to Supply Fiber Line and Bleaching Process to Tamil Nadu in India
HELSINKI, Finland, Nov. 3, 2005 (PRIMEZONE) -- Metso Paper will supply a new hardwood fiber line to Tamil Nadu Newsprint and Papers Ltd. in India. In addition, Metso Paper will supply a new bleaching process for the company's bagasse fiber line. The total value of the orders is approximately EUR 25 million. The new systems are scheduled to start up at the beginning of 2007. The order has been booked in the third quarter of 2005.
Royal Numico NV
Numico Sells Baby Cereals Business in Brazil
SCHIPHOL AIRPORT, Netherlands, Nov. 3, 2005 (PRIMEZONE) -- Royal Numico N.V. announces that the company has sold its baby cereals business in Brazil to Nutrimental S.A. Industria e Comercio de Alimentos -- a privately owned company -- for an undisclosed amount. The divestment of the Brazilian cereals business, which includes a manufacturing plant, marks the completion of Numico's portfolio rationalisation. Numico has now divested all businesses that do not meet the criteria of Numico's strategic mission to be a high-growth, high-margin specialised nutrition company. The transaction will not have a material financial impact on Numico's results.
Update on OMX's 24 Percent Ownership in EDX London
STOCKHOLM, Sweden, Nov. 3, 2005 (PRIMEZONE) -- EDX London Ltd, jointly owned by London Stock Exchange and OMX (76 and 24 percent respectively), offers trading and clearing in Scandinavian equity derivatives as well as over-the-counter equity derivatives services in London. During the period April-September 2005, EDX London traded a total of 10.1 million (9.2) contracts, mainly relating to Scandinavian equity derivatives. Although development of services for the over-the-counter equity derivatives market continued during the period, this service does not justify further investment. It is therefore today being announced in London Stock Exchange's Interim Report for April-September that an exceptional impairment loss has been recognized in EDX London. The total impairment in EDX London amounts of GBP 22 m, principally in respect of the impairment of goodwill. OMX owns 24 percent of EDX London, which is treated in OMX' accounts as an associated company.
Novartis Announces Leadership of New Vaccines and Diagnostics Business
BASEL, Switzerland, Nov. 3, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has designated Dr. Joerg Reinhardt, currently Global Head of Pharma Development, to become CEO of a new Novartis division that will combine Chiron Corporation's (Nasdaq:CHIR) vaccines and diagnostics business, pending regulatory and shareholder approvals. In this new role, Dr. Reinhardt will report directly to Dr. Daniel Vasella, the Chairman and CEO of Novartis.
Pharming Group N.V.
Pharming Announces Results for First Nine Months 2005
LEIDEN, Netherlands, Nov. 3, 2005 (PRIMEZONE) -- Highlights: upcoming product filings, licensing progress and pipeline expansion. Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today its financial results for the third quarter of 2005 and for the first nine months ended September 30, 2005. The Company highlighted upcoming product filings for recombinant human C1 inhibitor (rhC1INH) and its human lactoferrin product (rhLF), licensing progress and its pipeline expansion.